Mostrar el registro sencillo del ítem

dc.creatorHernández-Pando, R.
dc.creatorDe la Luz Streber, M.
dc.creatorOrozco, H.
dc.creatorArriaga, K.
dc.creatorPavón, L.
dc.creatorMarti, O.
dc.creatorLightman, S.L.
dc.creatorRook, G.A.W.
dc.date.accessioned2017-06-29T04:21:48Z
dc.date.available2017-06-29T04:21:48Z
dc.date.issued1998es_ES
dc.identifier269es_ES
dc.identifier.issn1460-2725es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/4963
dc.identifier.urihttps://doi.org/10.1093/qjmed/91.11.755es_ES
dc.language.isoenges_ES
dc.relation91 (11) 755-766 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleEmergent immunoregulatory properties of combined glucocorticoid and anti-glucocorticoid steroids in a model of tuberculosises_ES
dc.typearticlees_ES
dc.contributor.affiliationExperimental Pathology Laboratory, Department of Pathology, Instituto Nacional de la Nutricion, Salvador Zubiran, Mexico City.es_ES
dc.relation.jnabreviadoQJMes_ES
dc.relation.journalQJM : Monthly Journal of the Association of Physicianses_ES
dc.identifier.placeInglaterraes_ES
dc.date.published1998es_ES
dc.identifier.organizacionInstituto Mexicano de Psiquiatríaes_ES
dc.identifier.eissn1460-2393es_ES
dc.identifier.doi10.1093/qjmed/91.11.755es_ES
dc.description.monthNoves_ES
dc.description.abstractotrodiomaIn Balb-c mice with pulmonary tuberculosis, there is a switch from a protective Th1-dominated cytokine profile to a non-protective profile with a Th2 component. This switch occurs while the adrenals are undergoing marked hyperplasia. Treatment with the anti-glucocorticoid hormones dehydroepiandrosterone or 3 beta, 17 beta-androstenediol, during the period of adrenal hyperplasia, maintains Th1 dominance and is protective. We investigated the effects of these hormones as therapeutic agents by administering them from day 60, when the switch to the non-protective cytokine profile was already well established. Given at this time (day 60), doses that were protective when given early (from day 0) were rapidly fatal. A physiological dose of the glucocorticoid corticosterone was also rapidly fatal. However when the corticosterone and the anti-glucocorticoid (AED or DHEA) were co-administered, there was protection, with restoration of a Th1-dominated cytokine profile, enhanced DTH responses, and enhanced expression of IL-1 alpha and TNF alpha. Therefore this combination of steroids has an emergent property that is quite unlike that of either type of steroid given alone. It may be possible to exploit the ant-inflammatory properties of glucocorticoids while preserving a Th1 bias, by combining glucocorticoids with DHEA or suitable metaboliteses_ES
dc.subject.kwAdjuvants, Immunologic-Administration & dosagees_ES
dc.subject.kwAndrostenediols-Administration & dosagees_ES
dc.subject.kwAndrostenediols-Immunologyes_ES
dc.subject.kwAnimalses_ES
dc.subject.kwCorticosterone-Bloodes_ES
dc.subject.kwDehydroepiandrosterone-Administration & dosagees_ES
dc.subject.kwDehydroepiandrosterone-Immunologyes_ES
dc.subject.kwDrug Combinationses_ES
dc.subject.kwHypersensitivity-Immunologyes_ES
dc.subject.kwImmunohistochemistryes_ES
dc.subject.kwIn Situ Hybridizationes_ES
dc.subject.kwInterleukin-1es_ES
dc.subject.kwmetabolismes_ES
dc.subject.kwMalees_ES
dc.subject.kwMicees_ES
dc.subject.kwMice, Inbred BALB Ces_ES
dc.subject.kwSurvival Analysises_ES
dc.subject.kwTuberculosis, Pulmonary-Bloodes_ES
dc.subject.kwTuberculosis, Pulmonary-Drug therapyes_ES
dc.subject.kwTuberculosis, Pulmonary-Immunologyes_ES
dc.subject.kwTumor Necrosis Factor-alpha-Metabolismes_ES
dc.subject.kwAdjuvants, Immunologices_ES
dc.subject.kwAndrostenediolses_ES
dc.subject.kwDrug Combinationses_ES
dc.subject.kwInterleukin-1es_ES
dc.subject.kwTumor Necrosis Factor-alphaes_ES
dc.subject.kwCorticosteronees_ES
dc.subject.kwDehydroepiandrosteronees_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem